Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab monotherapy in Chinese patients with recurrent or refractory active chronic graft-versus-host disease
ChiCTR2500101465Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axatilimab in chronic graft-versus-host disease (cGVHD), sponsored by Peking University People's Hospital. Primary endpoints: Objective response and Frequency and severity of adverse events. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ChiCTR2500101465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101465.